Elan sends ISEQ reeling

The ISEQ-index suffered a massive blow this morning as pharmaceutical heavy weight Elan issued a warning to regulators that two more cases of brain disease have been linked to the company's multiple sclerosis drug Tysabri.

Elan sends ISEQ reeling

The ISEQ-index suffered a massive blow this morning as pharmaceutical heavy weight Elan issued a warning to regulators that two more cases of brain disease have been linked to the company's multiple sclerosis drug Tysabri.

The Elan share price collapsed by more than 50% on the after two new cases of the brain disease PML were identified in patients using its drug Tysabri.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €130 €65

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited